Transparency Market Research U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020
Published Date 2015-01-27
83 Page Report
Buy Now
Request Sample
Press Release
U.S. Vaccine Market Expected to Reach USD 17.3 Billion in 2020
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
U.S. Vaccine Market
REPORT DESCRIPTION
U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020
According to a new market report published by Transparency Market Research “U.S. Vaccine Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020,” the U.S. vaccine market was valued at USD 12.8 billion in 2013 and is expected to grow at a CAGR of 4.3% from 2014 to 2020, to reach an estimated value of USD 17.3 billion in 2020. Earlier, the only way to achieve immunity against a disease was through infection with the actual disease, which is known as naturally-acquired immunity. Today, a number of vaccines are available that are administered to boost immunity against various diseases. The U.S. Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) recommends vaccination against many diseases including hepatitis A, hepatitis B, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), polio, rabies, rotavirus, varicella and Japanese encephalitis, among others. The U.S. vaccine market is growing under the influence of factors such as rising awareness regarding vaccination through various governmental and non-profit organizations, extremely low risk of serious and fatal side effects associated with vaccines and burgeoning demand for adult vaccines. On the contrary, stringent regulatory approval process, high cost associated with new vaccine discovery and development, and burden of maintaining cold chain logistics to prevent loss of vaccine potency and efficacy are some major factors creating hindrance in the growth of vaccine market.
Browse the full U.S. Vaccine Market Report at : http://www.transparencymarketresearch.com/us-vaccine-market.html
The U.S. vaccine market is majorly segmented into human and animal vaccines. The market for U.S. human vaccines has been further classified into pediatric and adult vaccine markets. The pediatric vaccine market represented the larger segment by revenue in 2013. However, during the forecast period from 2014 to 2020, the market for adult vaccines is expected to expand at a higher CAGR than the pediatric vaccines market. One of the major reasons for this is the CDC’s recommendations to adults for immunization against several diseases such as flu, pneumococcal, meningococcal, HPV infection, chickenpox and hepatitis. The CDC’s
Transparency Market Research
2
U.S. Vaccine Market
recommendations to all U.S. citizens aged 6 months and older travelling abroad to be up-to-date on routine vaccines and travel vaccines, also contribute to the market growth of adult vaccines.
Get Free Sample Report U.S. Vaccine Market : http://www.transparencymarketresearch.com/sample/sample.php? flag=S&rep_id=553
On the basis of different antigens, the U.S. human vaccine market is segmented into hepatitis, influenza, meningococcal, pneumococcal, HPV, combination vaccines, and others. Of these, the combination vaccines segment held the largest share by revenue in 2013, though meningococcal vaccines are likely to form the fastest growing segment during the forecast period. This is primarily due to the anticipated launch of pipeline products in this segment during the forecast period. The U.S. human vaccine market is dominated by five major vaccine manufacturers: GlaxoSmithKline plc, Sanofi, Pfizer Ltd, Merck & Co., Inc., and Novartis International AG. These players collectively accounted for more than 85% of the total market revenue in 2013.
Browse the full U.S. Vaccine Market press release at : http://www.transparencymarketresearch.com/pressrelease/us-vaccine-marketresearch.htm
The U.S. animal vaccine market has been broadly classified as companion and livestock vaccine markets. The companion animal vaccine market segment has been further categorized into canine and feline, while the livestock vaccines market segment has been divided into porcine, bovine, ovine, poultry and equine sub-segments. Within the livestock vaccine market, bovine vaccine market represented the largest segment in terms of revenue in 2013. However, during the forecast period between 2014 and 2020, the poultry vaccine market is expected grow at the highest rate. Zoetis, Inc., Merck & Co., Inc. (Merck Animal Health), Sanofi (Merial, animal health division of Sanofi) and Boehringer Ingelheim are the leading players in the U.S. animal vaccine market.The
Transparency Market Research
3
U.S. Vaccine Market
U.S. vaccine market is segmented as follows:
U.S. Human Vaccine Market, by Type
Pediatric
Adult
U.S. Human Vaccine Market, by Antigen
Hepatitis (A & B)
Influenza
Meningococcal
Pneumococcal
Human Papillomavirus (HPV)
Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV)
Transparency Market Research
4
U.S. Vaccine Market
Others
U.S. Animal Vaccine Market, by Animal Type
Companion Animal Vaccine Market
Canine
Feline
Livestock Vaccine Market
Porcine
Bovine
Ovine
Poultry
Equine
TABLE OF CONTENT
Transparency Market Research
5
U.S. Vaccine Market
Chapter 1 Preface 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.3.1 Assumptions 1.3.2 Sources 1.3.2.1 Secondary Research 1.3.2.2 Primary Research 1.3.3 Models
Chapter 2 Executive Summary 2.1 Market Snapshot: U.S. Vaccine Market (2013 & 2020) 2.2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million)
Chapter 3 U.S. Vaccine Market Overview 3.1 Introduction 3.2 Vaccine Approval Regulatory Pathway 3.2.1 Major Steps: Vaccine Development and Commercialization 3.3 Drivers 3.3.1 Growing incidence of zoonotic diseases drives increased animal vaccination 3.3.2 Increasing consumption of chicken to augment the demand of poultry vaccines in the U.S.
Transparency Market Research
6
U.S. Vaccine Market
3.3.3 Extremely low risk of serious and fatal side effects associated with vaccines is a strong driver in the adoption of vaccines 3.3.4 Education and awareness through various governmental and non-profit organizations 3.4 Restraints 3.4.1 Strict regulatory pathway and high cost associated with new vaccine discovery and development 3.4.2 High cost associated with vaccine transportation, storage and handling 3.5 Opportunities 3.5.1 DNA vaccines hold immense potential for a number of human and animal diseases 3.5.2 The U.S. offers immense potential for adult vaccines market 3.6 Competitive Landscape 3.6.1 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %) 3.6.2 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %)
Chapter 4 U.S. Human Vaccine Market Revenue 4.1 Overview 4.1.1 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million) 4.1.2 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million) 4.1.3 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %) 4.1.4 Hepatitis 4.1.4.1 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.5 Influenza
Transparency Market Research
7
U.S. Vaccine Market
4.1.5.1 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.6 Meningococcal 4.1.6.1 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.7 Pneumococcal 4.1.7.1 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.8 Human Papillomavirus (HPV) 4.1.8.1 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.9 Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV) 4.1.9.1 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.1.10 Others 4.1.10.1 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million) 4.2 Pricing Analysis 4.2.1 Pricing Analysis: Hepatitis Vaccines 4.2.2 Pricing Analysis: Influenza Vaccines 4.2.3 Pricing Analysis: Meningococcal Vaccines 4.2.4 Pricing Analysis: Pneumococcal Vaccines 4.2.5 Pricing Analysis: Human Papillomavirus Vaccines (HPV) 4.2.6 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV) 4.2.7 Pricing Analysis: Other Vaccines
Chapter 5 U.S. Animal Vaccine Market Revenue, 2012 – 2020 (USD Million)
Transparency Market Research
8
U.S. Vaccine Market
5.1 Overview 5.1.1 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million) 5.1.2 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %) 5.2 Companion Animal Vaccines 5.2.1 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million) 5.2.2 Canine Vaccines 5.2.2.1 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.2.2.2 Pricing Analysis: Canine Vaccines 5.2.3 Feline Vaccines 5.2.3.1 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.2.3.2 Pricing Analysis: Feline Vaccines 5.3 Livestock Vaccines 5.3.1 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million) 5.3.2 Porcine Vaccines 5.3.2.1 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.2.2 Pricing Analysis: Porcine Vaccines 5.3.3 Bovine Vaccines 5.3.3.1 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.3.2 Pricing Analysis: Bovine Vaccines 5.3.4 Ovine Vaccines
Transparency Market Research
9
U.S. Vaccine Market
5.3.4.1 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.4.2 Pricing Analysis: Ovine Vaccines 5.3.5 Poultry Vaccines 5.3.5.1 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.6 Equine Vaccines 5.3.6.1 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million) 5.3.6.2 Pricing Analysis: Equine Vaccines
Chapter 6 Recommendations 6.1 Focus on cost-effective vaccine manufacturing 6.2 Focus on developing technologically advanced vaccines such as DNA vaccines
Chapter 7 Company Profiles 7.1 Boehringer Ingelheim 7.1.1 Company Overview 7.1.2 Financial Overview 7.1.3 Product Portfolio 7.1.4 Business Strategies 7.1.5 Recent Developments 7.2 GlaxoSmithKline plc 7.2.1 Company Overview
Transparency Market Research
10
U.S. Vaccine Market
7.2.2 Financial Overview 7.2.3 Product Portfolio 7.2.4 Business Strategies 7.2.5 Recent Developments 7.3 Merck & Co., Inc. 7.3.1 Company Overview 7.3.2 Financial Overview 7.3.3 Product Portfolio 7.3.4 Business Strategies 7.3.5 Recent Developments 7.4 Novartis International AG 7.4.1 Company Overview 7.4.2 Financial Overview 7.4.3 Product Portfolio 7.4.4 Business Strategies 7.4.5 Recent Developments 7.5 Pfizer, Inc. 7.5.1 Company Overview 7.5.2 Financial Overview 7.5.3 Product Portfolio 7.5.4 Business Strategies
Transparency Market Research
11
U.S. Vaccine Market
7.5.5 Recent Developments 7.6 Sanofi SA 7.6.1 Company Overview 7.6.2 Financial Overview 7.6.3 Product Portfolio 7.6.4 Business Strategies 7.6.5 Recent Developments 7.7 Zoetis, Inc. 7.7.1 Company Overview 7.7.2 Financial Overview 7.7.3 Product Portfolio 7.7.4 Business Strategies 7.7.5 Recent Developments List of Figures
FIG. 1 U.S. Vaccine: Market Segmentation FIG. 2 U.S. Human Vaccine Market, by Antigen, 2013 (USD Million) FIG. 3 Major Steps: Vaccine Development and Commercialization FIG. 4 U.S. Human Vaccine Market Share Analysis, by Key Players, 2013 (Value %) FIG. 5 U.S. Animal Vaccine Market Share Analysis, by Key Players, 2013 (Value %) FIG. 6 Comparative Analysis: U.S. Human Vaccine Market Revenue, by Antigen, 2013 & 2020 (Value %)
Transparency Market Research
12
U.S. Vaccine Market
FIG. 7 U.S. Hepatitis Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 8 U.S. Influenza Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 9 U.S. Meningococcal Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 10 U.S. Pneumococcal Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 11 U.S. Human Papillomavirus Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 12 U.S. Combination Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 13 U.S. Other Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 14 Comparative Analysis: U.S. Animal Vaccine Market Revenue, by Animal Type, 2013 & 2020 (Value %) FIG. 15 U.S. Canine Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 16 U.S. Feline Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 17 U.S. Porcine Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 18 U.S. Bovine Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 19 U.S. Ovine Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 20 U.S. Poultry Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 21 U.S. Equine Vaccine Market Revenue, 2012 – 2020 (USD Million) FIG. 22 Boehringer Ingelheim Vetmedica: Annual Revenue, by Segment, 2011 – 2013 (USD Million) FIG. 23 GlaxoSmithKline plc: Annual Revenue, by Segment, 2011 – 2013 (USD Million) FIG. 24 Merck & Co., Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million) FIG. 25 Novartis International AG: Annual Revenue, by Segment, 2011 – 2013 (USD Million) FIG. 26 Pfizer, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million)
Transparency Market Research
13
U.S. Vaccine Market
FIG. 27 Sanofi SA: Annual Revenue, by Segment, 2011 – 2013 (USD Million) FIG. 28 Zoetis, Inc.: Annual Revenue, by Segment, 2011 – 2013 (USD Million) List of Tables
TABLE 1 Market Snapshot: U.S. Vaccine Market (2013 & 2020) TABLE 2 U.S. Human Vaccine Market Revenue, by Type, 2012 – 2020 (USD Million) TABLE 3 U.S. Human Vaccine Market Revenue, by Antigen, 2012 – 2020 (USD Million) TABLE 4 Pricing Analysis: Hepatitis Vaccines TABLE 5 Pricing Analysis: Influenza Vaccines TABLE 6 Pricing Analysis: Meningococcal Vaccines TABLE 7 Pricing Analysis: Pneumococcal Vaccines TABLE 8 Pricing Analysis: Human Papillomavirus Vaccines (HPV) TABLE 9 Pricing Analysis: Combination Vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV) TABLE 10 Pricing Analysis: Other Vaccines TABLE 11 U.S. Animal Vaccine Market Revenue, by Animal Type, 2012 – 2020 (USD Million) TABLE 12 U.S. Companion Animal Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million) TABLE 13 Pricing Analysis: Canine Vaccines TABLE 14 Pricing Analysis: Feline Vaccines TABLE 15 U.S. Livestock Vaccine Market Revenue, by Segment, 2012 – 2020 (USD Million) TABLE 16 Pricing Analysis: Porcine Vaccines TABLE 17 Pricing Analysis: Bovine Vaccines
Transparency Market Research
14
U.S. Vaccine Market
TABLE 18 Pricing Analysis: Ovine Vaccines TABLE 19 Pricing Analysis: Equine Vaccines TABLE 20 Boehringer Ingelheim: Expenses & Revenue, 2011 – 2013 (USD Million) TABLE 21 GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2013 (USD Million) TABLE 22 Merck & Co., Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) TABLE 23 Novartis International AG: Expenses & Revenue, 2011 – 2013 (USD Million) TABLE 24 Pfizer, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) TABLE 25 Sanofi SA: Expenses & Revenue, 2011 – 2013 (USD Million) TABLE 26 Zoetis, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact
Transparency Market Research
15
U.S. Vaccine Market
Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse The Market Research Blog : http://researchandreports.wordpress.com/ http://www.transparencymarketresearch.com
Transparency Market Research
16